Authors: Claire P. Reese, Petra Brhlikova, Allyson M. Pollock Abstract Summary We conducted a critical appraisal of published Phase 2 and 3 efficacy trials in relation to the prevention of cervical cancer in women. Our analysis shows the trials themselves generated significant uncertainties undermining claims of efficacy in these data. There were 12 randomised control […]
Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness
Published in the Journal of the Royal Society of Medicine; June 2012 105:229 Authors: I Mattheij,1 AM Pollock,2 P Brhlikova3 Summary The Indian government suspended research in April 2010 on the feasibility and safety of human papillomavirus (HPV) vaccine in two Indian states (Andhra Pradesh and Gujarat) amid public concerns about its safety. This paper describes cervical cancer […]
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
The Lancet, Volume 374, Issue 9686, Pages 301 – 314, 25 July 2009 Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and associated precancerous lesions in an event-triggered interim analysis of the phase III randomised, double-blind, controlled PApilloma TRIal against Cancer In young Adults […]
HPV DNA testing over 50 percent more sensitive than cytology testing
Science Centric | 9 July 2010 10:46 GMT HPV DNA testing for precancers and cervical cancers is over 50 per cent more sensitive than cytology testing for the same conditions a community-based study in Mexico has revealed. Results of the largest HPV DNA primary screening study ever to be performed in a Latin American country […]
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection
A Randomized Trial JAMA. 2007;298:743-753. Main Outcome Measures Presence of HPV DNA was determined in cervical specimins by a molecular hybridization assay using chemiluminescence with HPV RNA probes and by polymerase chain reaction using SPF10 primers and a line probe assay detection system before vaccination and by polymerase chain reaction after vaccination. We compared rates of […]
